2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses
Peeva E, Yamaguchi Y, Ye Z, King B, Picardo M, Sloan A, Ezzedine K, Del Duca E, Estrada Y, Hassan‐Zahraee M, He W, Hyde C, Bar J, Facheris P, Guttman‐Yassky E. Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses. Experimental Dermatology 2024, 33: e15177. PMID: 39304339, DOI: 10.1111/exd.15177.Peer-Reviewed Original ResearchConceptsFitzpatrick skin typeNonsegmental vitiligoSerum levelsFacial Vitiligo Area Scoring IndexTreatment-emergent adverse eventsWeek 4Fitzpatrick skin types I-IIIFitzpatrick skin types IV-VINonsegmental vitiligo patientsResponders to therapySkin typeIL-22 expression levelsDark skinImmune dysregulationAdverse eventsIL-9No significant changesVitiligo patientsRe-pigmentationRitlecitinibIL-22Score indexPatientsCLM-1Weeks
2022
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Ezzedine K, Peeva E, Yamaguchi Y, Cox L, Banerjee A, Han G, Hamzavi I, Ganesan A, Picardo M, Thaçi D, Harris J, Bae J, Tsukamoto K, Sinclair R, Pandya A, Sloan A, Yu D, Gandhi K, Vincent M, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal Of The American Academy Of Dermatology 2022, 88: 395-403. PMID: 36370907, DOI: 10.1016/j.jaad.2022.11.005.Peer-Reviewed Original ResearchConceptsNonsegmental vitiligoLoading doseScoring IndexPercent changePhase 2b clinical trialExtension periodPhase 2b trialPrimary efficacy endpointSerious adverse eventsChronic autoimmune disorderDose-dependent trendEfficacy endpointAdverse eventsWeek 24Autoimmune disordersClinical trialsStable vitiligoPatientsVitiligoSignificant differencesTreatmentDoseBaselineTrialsWeeks
2020
Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity?
Peterson D, King B. Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity? Journal Of The American Academy Of Dermatology 2020, 84: e63-e64. PMID: 32891783, DOI: 10.1016/j.jaad.2020.08.120.Peer-Reviewed Original Research
2018
Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy
Kim R, Heaton H, Liu LY, King BA. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. JAMA Dermatology 2018, 154: 370-371. PMID: 29387870, DOI: 10.1001/jamadermatol.2017.5778.Peer-Reviewed Original Research
2017
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal Of The American Academy Of Dermatology 2017, 77: 675-682.e1. PMID: 28823882, PMCID: PMC6233876, DOI: 10.1016/j.jaad.2017.05.043.Peer-Reviewed Original ResearchConceptsTreatment of vitiligoJAK inhibitorsConsecutive patientsInhibitor tofacitinibJanus kinase inhibitor tofacitinibJAK inhibitor monotherapyRetrospective case seriesUltraviolet B phototherapyT-cell mediatorsBody surface areaJanus kinase inhibitorSeverity of diseaseB phototherapyInhibitor monotherapyCase seriesAutoimmune responseCell mediatorsAutoimmune diseasesCutaneous depigmentationLight exposureRetrospective natureStudy populationExisting therapiesControl groupTofacitinibJAK inhibitors in dermatology: The promise of a new drug class
Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal Of The American Academy Of Dermatology 2017, 76: 736-744. PMID: 28139263, PMCID: PMC6035868, DOI: 10.1016/j.jaad.2016.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAlopecia AreataAnti-Inflammatory AgentsAzetidinesClinical Trials as TopicDermatitis, AtopicDermatologic AgentsHumansJanus KinasesMolecular Targeted TherapyNitrilesPiperidinesProtein Kinase InhibitorsPsoriasisPurinesPyrazolesPyrimidinesPyrrolesSignal TransductionSkin DiseasesSulfonamidesVitiligoConceptsJAK inhibitorsSoluble inflammatory mediatorsNew drug classesUseful therapeutic strategyDifferent proinflammatoryAtopic dermatitisInflammatory mediatorsInflammatory dermatosesAlopecia areataDrug classesJanus kinase-signal transducerTherapeutic strategiesJAK inhibitionDermatologic therapyKinase-signal transducerTargeted therapeuticsActivator of transcriptionDermatologyJAK-STATInhibitorsPromising new classEarlier reportsInhibition
2015
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy
Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatology 2015, 151: 1110-1112. PMID: 26107994, DOI: 10.1001/jamadermatol.2015.1520.Peer-Reviewed Original ResearchConceptsJanus kinase inhibitorTreatment of vitiligoKinase inhibitorsPathogenesis-directed therapyPathogenesis of vitiligoOral JanusSignificant repigmentationTherapeutic optionsCommon conditionEffective treatmentVitiligoAdditional studiesTofacitinib citrateTreatmentInhibitorsPatientsPathogenesisRepigmentationTherapy